The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer
Open accessAbstract
Cardiotoxicity, also referred to as drug-induced cardiac injury, is an issue associated with the use of some small-molecule kinase inhibitors and antibody-based therapies targeting signaling pathways in cancer. Although these drugs have had a major impact on cancer patient survival, data have implicated kinase-targeting agents such as sunitinib, imatinib, trastuzumab, and sorafenib in adversely affecting cardiac function in a subset of treated individuals. In many cases, adverse cardiac events in the clinic were not anticipated based on preclinical safety evaluation of the molecule. In order to support the development of efficacious and safe kinase inhibitors for the treatment of cancer and other indications, new preclinical approaches and screens are required to predict clinical cardiotoxicity. Laboratory investigations into the underlying molecular mechanisms of heart toxicity induced by these molecules have identified potentially common themes including mitochondrial perturbation and modulation of adenosine monophosphate-activated protein kinase activity. Studies characterizing cardiac-specific kinase knockout mouse models have developed our understanding of the homeostatic role of some of these signaling mediators in the heart. Therefore, when considering kinases as potential future targets or when examining secondary pharmacological interactions of novel kinase inhibitors, these models may help to inform us of the potential adverse cardiac effects in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“…cytoprotective role in the body, mediated via four broad categories of activity: increasing the ratio of oxygen supply to demand, protecting against ischemic damage by cell conditioning , triggering anti-inflammatory responses, and the promotion of angiogenesis (Jacobson and Gao, 2006 ).”
BackgroundAngiogenesis Inhibitors and Hypertension: An Emerging Issue
Sica, D. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5740 · Cited by 127
Cited by
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
The clinical toxicology of caffeine: A review and case study
Willson, C. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.002 · Cited by 289
Metadata
- Authors
- Mellor, H. R., Bell, A. R., Valentin, J.-P., & Roberts, R. R. A.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-22
- Volume
- 120
- Issue
- 1
- Pages
- 14-32
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2167665047
- Cited by
- 168
- References
- 4
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer. https://app.cochat.ai/papers/10.1093/toxsci/kfq378
- The paper
- Mellor, H. R., Bell, A. R., Valentin, J.-P., & Roberts, R. R. A. (2011). Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfq378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.